A-375 - Cell Line (ID:50060)
| HMS LINCS ID: | 50060 |
| Name: | A-375 |
| Alternative Names: | A375 |
| LINCS ID: | LCL-1235 |
| Alternative ID: | CLO_0001582 |
| Parent Cell Line: | |
| Reference Source: | ATCC CRL-1619 |
| Organism: | Homo sapiens |
| Organ: | skin |
| Tissue: | |
| Cell Type: | epithelial |
| Details of Cell Type: | |
| Donor Sex: | female |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:1909, malignant melanoma |
| Details of Disease: | |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | COSS906793 |
| Verification Reference Profile: | DNA Profile (STR, source: ATCC): Amelogenin: X CSF1PO: 11,12 D13S317: 11,14 D16S539: 9 D5S818: 12 D7S820: 9 THO1: 8 TPOX: 8,10 vWA: 16,17 |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0 deg C Subculturing protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37 deg C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37 deg C. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended Medium Renewal: Every 2 to 3 days |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2012-05-01 |
| Most Recent Update: | 2016-07-12 |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20087 | Sorafenib KiNativ -- dose response experiment | KiNativ |
| 20088 | GW-5074 KiNativ -- dose response experiment | KiNativ |
| 20089 | SB590885 KiNativ -- dose response experiment | KiNativ |
| 20090 | PLX-4720 KiNativ -- dose response experiment | KiNativ |
| 20091 | AZ-628 KiNativ -- dose response experiment | KiNativ |
| 20092 | PLX4032 KiNativ -- dose response experiment | KiNativ |
| 20093 | HG-6-64-01 KiNativ -- single dose experiment | KiNativ |
| 20213 | JNK-IN-8 KiNativ -- single dose experiment | KiNativ |
| 20272 | Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2) | Microscopy/Imaging |
| 20273 | Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of three compounds (viability/apoptosis dataset 2 of 2) | Microscopy/Imaging |
| 20274 | Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 1 of 4) | Microscopy/Imaging |
| 20275 | Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 2 of 4) | Microscopy/Imaging |
| 20276 | Protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with Vemurafenib in combination with chromatin-targeting compounds (immunofluorescence dataset 3 of 4) | Microscopy/Imaging |
| 20277 | Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 4 of 4) | Microscopy/Imaging |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Catalog ID | Provider Batch ID |
|---|---|---|---|
| 50060-1 | ActivX Biosciences, Inc. | ||
| 50060-2 | Nienke Moret (Harvard Medical School) |